EP3515909A1 — Lim kinase inhibitors, pharmaceutical composition and method of use in limk-mediated diseases
Assigned to Cellipse · Expires 2019-07-31 · 7y expired
What this patent protects
The present invention relates to LIM Kinase inhibitors of Formula (I) and pharmaceutically acceptable salts or solvates thereof, wherein R 1 , R 2 , R 3 , R 4 , X 1 , X 2 , X 3 , Y 1 , Y 2 and Z are as defined in the claims, and their use for the treatment and/or prevention of L…
USPTO Abstract
The present invention relates to LIM Kinase inhibitors of Formula (I) and pharmaceutically acceptable salts or solvates thereof, wherein R 1 , R 2 , R 3 , R 4 , X 1 , X 2 , X 3 , Y 1 , Y 2 and Z are as defined in the claims, and their use for the treatment and/or prevention of LIMK-mediated diseases.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.